2018
|
Sign up to set email alerts
|

Abstract: Pemafibrate significantly ameliorated lipid abnormalities and was well tolerated in patients with type 2 diabetes comorbid with hypertriglyceridemia.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
68
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 102 publications
(77 citation statements)
references
References 39 publications
(42 reference statements)
9
68
0
Order By: Relevance
“…After treatment period 1, treatment period 2 was initiated, from week 24 to week 52, with the placebo changed to 0.2 mg/d pemafibrate. The main results from treatment period 1 have been reported previously . This report summarizes the results including treatment period 2, which spanned 52 weeks.…”
Section: Introductionmentioning
confidence: 71%
See 4 more Smart Citations
“…After treatment period 1, treatment period 2 was initiated, from week 24 to week 52, with the placebo changed to 0.2 mg/d pemafibrate. The main results from treatment period 1 have been reported previously . This report summarizes the results including treatment period 2, which spanned 52 weeks.…”
Section: Introductionmentioning
confidence: 71%
“…Figure S2 shows the disposition of participants. Participant characteristics have been reported previously …”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations